Lupin Gets SBTi Approval For Emission Reduction Goals 
Pharma

Lupin Gets SBTi Approval For Emission Reduction Goals

By Team VOH

Lupin Limited has received validation from the Science Based Targets initiative (SBTi) for its greenhouse gas emissions reduction targets across Scope 1, Scope 2 and Scope 3, aligning its climate commitments with the Paris Agreement’s 1.5°C pathway. The validation places Lupin among a limited group of companies globally to achieve comprehensive SBTi approval covering all emission scopes within a year of setting its targets.

The approved targets include a 42 per cent reduction in absolute Scope 1 and Scope 2 emissions by FY2030, using FY2023 as the base year. Lupin has also committed to reducing Scope 3 emissions by 61.07 per cent by FY2033 from an FY2024 baseline. Scope 3 reductions will cover purchased goods and services, fuel- and energy-related activities, upstream and downstream transportation and distribution, business travel, employee commuting, processing and use of sold products, and franchises.

The targets have been validated under SBTi’s latest criteria and are aligned with a science-based pathway to limit global temperature rise. The validation reflects the integration of sustainability into Lupin’s financial and operational planning, with a focus on expanding renewable energy use, improving energy efficiency and deploying low-carbon technologies across its global operations.

The Science Based Targets initiative independently evaluates corporate climate targets and promotes emissions reductions consistent with global climate goals.

Also Read

SCROLL FOR NEXT